Unknown

Dataset Information

0

Exploiting the promiscuity of imatinib.


ABSTRACT: The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.

SUBMITTER: Lee SJ 

PROVIDER: S-EPMC2689438 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploiting the promiscuity of imatinib.

Lee Shun J SJ   Wang Jean Y J JY  

Journal of biology 20090415 3


The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor. ...[more]

Similar Datasets

| S-EPMC3138741 | biostudies-literature
| S-EPMC6890836 | biostudies-literature
| S-EPMC4790474 | biostudies-literature
| S-EPMC6470038 | biostudies-literature
| S-EPMC8378672 | biostudies-literature
| S-EPMC2925430 | biostudies-literature
2018-05-14 | GSE114358 | GEO
| S-EPMC3053118 | biostudies-literature
| S-EPMC4207249 | biostudies-literature
| S-EPMC4215207 | biostudies-literature